Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; ...
The omicron variant of the coronavirus could lead to more infections among vaccinated people but they will most likely remain protected from a severe course of illness, according to the inventor of ...
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older The KP.2 adaptation is based on FDA ...
Pfizer and BioNTech’s bivalent vaccine contains 15-µg of mRNA encoding the wild-type spike -protein of SARS-CoV-2, which is present in the original Pfizer-BioNTech COVID-19 vaccine and 15-µg of mRNA ...
Pfizer and BioNTech also filed an application with the EMA for the Omicron BA.1-adapted bivalent COVID-19 vaccine in July which is currently under review by the Agency. Both the Omicron BA.1-adapted ...
Pfizer and BioNTech have submitted a request to the FDA for Emergency Use Authorization of an omicron-adapted COVID-19 booster dose for individuals 12 years of age and older. Pending authorization, ...
A third shot of the children's dose of Pfizer/BioNTech's Covid-19 vaccine raised Omicron-fighting antibodies by 36 times in kids 5 through 11 years of age, the companies said in a news release ...
Vaccine makers are racing to find out whether current COVID-19 jabs provide adequate protection against omicron and how to adapt them to the strain. Moderna on Friday announced its strategy to address ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results